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Abstract
Optineurin is a ubiquitously expressed multifunctional cytoplasmic protein encoded by OPTN gene. The expression of
optineurin is induced by various cytokines. Here we have investigated the molecular mechanisms which regulate optineurin
gene expression and the relationship between optineurin and nuclear factor kB (NF-kB). We cloned and characterized
human optineurin promoter. Optineurin promoter was activated upon treatment of HeLa and A549 cells with tumor
necrosis factor a (TNFa). Mutation of a putative NF-kB-binding site present in the core promoter resulted in loss of basal as
well as TNFa-induced activity. Overexpression of p65 subunit of NF-kB activated this promoter through NF-kB site.
Oligonucleotides corresponding to this putative NF-kB-binding site showed binding to NF-kB. TNFa-induced optineurin
promoter activity was inhibited by expression of inhibitor of NF-kB (IkBa) super-repressor. Blocking of NF-kB activation
resulted in inhibition of TNFa-induced optineurin gene expression. Overexpressed optineurin partly inhibited TNFa-induced
NF-kB activation in Hela cells. Downregulation of optineurin by shRNA resulted in an increase in TNFa-induced as well as
basal NF-kB activity. These results show that optineurin promoter activity and gene expression are regulated by NF-kB
pathway in response to TNFa. In addition these results suggest that there is a negative feedback loop in which TNFa-
induced NF-kB activity mediates expression of optineurin, which itself functions as a negative regulator of NF-kB.
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Introduction
Optineurin is a cytoplasmic protein that is ubiquitously
expressed although it shows higher level of expression in retina,
brain, heart, skeletal muscle, placenta and kidney [1–4]. Mutations
in optineurin are associated with certain glaucomas, a group of eye
diseases that cause blindness [5–14]. Optineurin interacts with
several proteins such as Rab8, Huntingtin, myosin VI, RIP,
transcription factor IIIA, metabotropic glutamate receptor, TBK1
etc [1,15–20]. Based on interaction with myosin VI, its role in
vesicular trafficking between Golgi and plasma membrane has
been proposed [17]. Recently it has been shown that optineurin
negatively regulates TNFa-induced NF-kB activation by binding
to polyubiquitinated RIP (19). Towards the C-terminal end, a
ubiquitin-binding domain has been identified in optineurin, which
is also present in NEMO, a sub-unit of protein kinase IKK
complex involved in NF-kB regulation [19]. Optineurin plays a
role in the regulation of expression of many genes [21] although
the mechanisms involved are yet to be elucidated. Optineurin gene
and protein expression is induced by treatment of cells with TNFa
and interferons [1,16]. However the mechanisms by which these
cytokines activate optineurin gene expression are not known.
TNFa is a cytokine that plays an important role in
inflammation, immune response, regulation of cell death, cell
proliferation and cancer [22,23]. The biological effects of TNFa
are mediated by its binding to trimeric receptor, TNFR-1 which
results in activation of two important signalling pathways that lead
to activation of transcription factor NF-kB and caspase-8. NF-kB
comprises a family of inducible transcription factors that serve as
important regulators of host immune response and inflammatory
response [22,23]. NF-kB is also involved in protecting cells from
apoptosis by inducing many anti-apoptotic genes. NF-kB activity is
regulated through association with an inhibitor, IkB which keeps
NF-kB in the cytoplasm [22,23]. NF-kB is activated in the
trabecular meshwork cells in glaucoma where it is involved in
cytoprotection in response to oxidative stress [24].
Overexpressed optineurin provides protection to NIH 3T3 cells
against cell death induced by high level of oxidative stress [4].
Recently we have shown that overexpression of normal optineurin
sensitizes RGC-5 cells to TNFa-induced cell death whereas in HeLa
cells it reduces TNFa-induced cell death [25]. It is likely that altered
level of endogenous optineurin may affect survival of cells under
certain conditions of stress. It has been suggested that reduction in
expression of optineurin due to mutation in the coding region, rather
than altered function may contribute to the development of
glaucoma [19]. Therefore it is important to understand the
molecular mechanisms which regulate the level of optineurin.
Here we have investigated the molecular mechanisms which
regulate optineurin gene expression, and also studied the
relationship between optineurin and NF-kB. We have cloned
and characterized human optineurin promoter. The results
presented here show that optineurin promoter activity induced
by TNFa is regulated by NF-kB, which itself is in turn, negatively
regulated by optineurin.
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5114
Results
TNFa has been shown to induce optineurin gene and protein
expression in HeLa and some other cells [1,16]. To understand
the molecular mechanisms involved in TNFa-induced optineurin
gene expression we used human lung carcinoma cell line A549
which is responsive to TNFa. Initially we confirmed that TNFa
treatment increases optineurin gene expression in A549 cells in a
time-dependent manner as determined by real time RT-PCR
analysis (Fig. 1A). The optineurin mRNA level increased by
3 hours of TNFa treatment reaching maximum level after
6 hours. The optineurin mRNA level remained at increased level
even after 24 hours of treatment with TNFa. The level of
optineurin protein increased gradually upon TNFa treatment and
reached high level after 24 hours (Fig. 1B). In contrast IRF-1
protein level showed a transient increase after 3 hours of TNFa
treatment and declined thereafter (Fig. 1B).
TNFa activates optineurin promoter
We cloned about 1 kb of DNA sequence upstream of human
optineurin cDNA sequence by designing appropriate primers. This
putative optineurin promoter sequence matched completely with the
sequence reported in human genome data base. This putative
promoter was cloned in pGL-3 promoterless vector upstream of
luciferase reporter gene. This promoter-reporter plasmid (FP) was
transfected in HeLa cells and after 24 h these cells were lysed for
reporter assays. This promoter showed 147-fold higher activity than
the promoterless vector (figure not shown). The activity of this
promoter was increased by 2.3-fold upon treatment of cells with
TNFa in A549 cells (Fig. 1C) and by 60% in HeLa cells (Fig. 1D).
The nucleotide sequence of this 1077 bp putative promoter,
which includes 221 bp of exon-1, is shown in Figure 2A. There are
4 splice variants reported for optineurin mRNA in the database
which differ in their 59-untranslated region but code for the same
577 amino acid protein (Accession Nos. NM_001008211,
NM_001008212, NM_001008213 and NM_021980). Exon-1 is
present in all these 4 variants. The beginning of exon-1 is denoted
as +1. Analysis of this promoter showed several putative Sp1 sites
and one NF-kB site located immediately upstream of transcription
start site (Fig. 2A). There is no TATA box or initiator element
present in this promoter. Putative binding sites for heat shock
factors, HSF1 and HSF2, MyoD, neuron-restrictive silencing
factor (NRSF, also known as REST) and cyclic AMP response
element binding protein (CREB) were also identified. A smaller
promoter was made which contained putative Sp1 sites and the
NF-kB site (2136 to +221; named DP). This smaller promoter was
activated by TNFa as the full length promoter in A549 and HeLa
cells (Fig. 1C, D). The smaller promoter showed more basal
Figure 1. Induction of optineurin gene expression and promoter activation by TNFa. (A), A549 cells were treated with TNFa (10 ng/ml) for
indicated time (3–24 hours). Total RNA was then isolated and the level of optineurin mRNA was determined by real time RT-PCR. GAPDH was used as
a control. (B) Effect of TNFa on optineurin protein level. A549 cells were treated with TNFa (10 ng/ml) for indicated time. The cell lysates were then
prepared for immunoblotting which was performed using antibodies against optineurin, IRF-1 and tubulin (loading control). The numbers at the top
indicate relative amount of protein. Activation of optineurin promoter by TNFa in A549 cells (C) or HeLa cells (D). Cells grown in 24 well plates were
transfected with 100 ng of optineurin promoter-reporter plasmid (full length construct pGL-FP or deletion construct pGL-DP) along with
pCMV.SPORT b-gal plasmid. After 6 hours of transfection TNFa was added (10 ng/ml). After another 18 hours cell lysates were prepared for reporter
assays. Luciferase activities relative to untreated control (taken as 1.0) are shown (n= 3) after normalizing with b-galactosidase enzyme activities.
doi:10.1371/journal.pone.0005114.g001
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Figure 2. Effect of mutation of putative NF-kB site in optineurin promoter on TNFa-induced activity. (A) Nucleotide sequence of human
optineurin promoter. Putative transcription factor binding sites for various transcription factors such as Sp1, NF-kB, MyoD, HSF1, HSF2, NRSF and
CREB are shown. The 59 mRNA (exon 1) sequence is shown in italics. First nucleotide of optineurin mRNA is taken as transcription start site (+1),
indicated by an arrow. (B) Schematic representation of various promoter reporter constructs used for experiments in C, D. Full length promoter (FP),
deleted promoter (DP) and their NF-kB site mutants mFP and mDP are shown. The nucleotide sequence of putative NF-kB site is shown and the 3
nucleotides which were mutated are underlined. (C) Mutant or normal full length optineurin promoter constructs (mFP or FP) were transfected in
A549 cells and after 6 hours of transfection TNFa was added. Cell lysates were prepared after 24 hours of transfection for reporter assays. Luciferase
activities relative to untreated control promoter (taken as 1.0) are shown (n = 3). (D), The same experiment as in (C) was carried out using deleted
promoter, DP, or its mutant, mDP.
doi:10.1371/journal.pone.0005114.g002
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activity than the full length promoter in A549 as well as in HeLa
cells (Fig. 1C, D). These results showed that the DNA sequence
elements which mediate TNFa-induced as well as basal promoter
activity are present in the small promoter. In addition these results
suggest that a negative regulatory element is present in sequences
upstream of the minimal promoter.
Role of NF-kB in optineurin promoter activation
One of the important signalling pathways induced by TNFa
results in the activation of transcription factor NF-kB. Therefore
we mutated the putative NF-kB site in optineurin promoter and
analysed the effect of this mutation on reporter activity. Three
nucleotides in the core sequence of putative NF-kB binding site
were mutated (GGG changed to CTC, Fig. 2B). Mutation of NF-
kB site in full length as well as minimal promoter resulted in nearly
complete loss of activation by TNFa in A549 cells (Fig. 2C, D). In
addition, basal promoter activity was also significantly reduced in
full length as well as minimal promoter (Fig. 2C, D). These results
showed that NF-kB site is required for activation of optineurin
promoter by TNFa. In addition our results suggest that NF-kB site
is required for basal promoter activity.
A synthetic oligonucleotide corresponding to putative NF-kB
site present in the optineurin promoter was used for gel shift assay
(Fig. 3A). The oligonucleotide was labelled with 32P and incubated
with nuclear extract prepared from A549 cells treated with TNFa
for 15 min. Binding to this oligonucleotide was competed out with
50-fold excess of unlabeled self oligonucleotide and also with
consensus NF-kB-binding oligonucleotide (Fig. 3B) but not by a
mutant oligonucleotide in which NF-kB site was inactivated by
substitution of 3 nucleotides (Fig. 3B). Preincubation of the nuclear
extract with p65 NF-kB antibody resulted in the super shift of the
band. Gel shift assay was also carried out with nuclear extract from
control untreated cells which did not show the upper band shifted
by p65 antibody (Figure 3C). These results along with mutational
analysis of the promoter show that a functional NF-kB-binding site
is present in optineurin promoter.
The gel shift assay showed that p65 was able to bind NF-kB site
present in the optineurin promoter. To further analyse the role of
p65 NF-kB, A549 cells were transfected with optineurin promoter-
reporter plasmid with or without p65 expression plasmid.
Coexpression of p65 resulted in an increase in promoter activity
but the mutant promoter (in which NF-kB site was abrogated) was
not activated by p65 (Fig. 4A).
IkB inhibits optineurin promoter activity
In resting cells most of the NF-kB remains inactive due to its
sequestration in the cytoplasm by a group of inhibitory proteins
known as inhibitors of kB (IkB). Upon stimulation by a cytokine
like TNFa, IkBs are rapidly phosphorylated and then degraded by
ubiquitin proteasome pathway resulting in the nuclear transloca-
tion of NF-kB. Since NF-kB activation depends on IkB, we looked
into the effect of IkB on optineurin promoter activity. For this
purpose we used a super-repressor form of IkBa in which two
serine residues (S32, S36) are mutated so that it is not
phosphorylated or degraded. Optineurin promoter reporter
plasmids were transfected with or without IkBa super-repressor
plasmid in A549 cells. After 6 hours of transfection TNFa was
added. TNFa increased the promoter activity by 2.6 fold.
Overexpression of IkBa super-repressor abrogated the TNF-a
induced activation of the promoter. Basal activity of the promoter
was also reduced upon coexpression of IkBa (Fig. 4B). These
results suggest that optineurin promoter activity is regulated by
IkB-NF-kB pathway in response to TNFa.
NF-kB activation is required for TNFa-induced optineurin
gene expression
Our experiments described so far suggested that NF-kB plays an
important role in optineurin promoter activation by TNFa. We next
examined the role of NF-kB in optineurin gene expression in
response to TNFa. For this purpose we used proteasome inhibitor
MG132 which inhibits NF-kB activation by preventing degradation
of IkB [26]. A549 cells were pretreated with MG132 for 30 min and
then treated with TNFa for 6 hours. Blocking of NF-kB activation
by MG132 resulted in inhibition of TNFa-induced optineurin gene
expression as determined by real time RT-PCR analysis (Fig. 4C).
Blocking of NF-kB activation also resulted in reduced level of TNFa-
induced optineurin protein level (Fig. 4D). We also used NF-kB
inhibitor SN-50 to check its effect on TNFa-induced optineurin gene
expression. Pretreatment of A549 cells with SN-50 resulted in
inhibition of TNFa-induced optineurin gene expression (Fig. 4E).
Optineurin and E50K mutant inhibit activation of NF-kB
Various lines of evidence suggest that NF-kB is a regulator of
optineurin gene expression. Some targets of NF-kB are known to
regulate NF-kB activity in signaling pathways [22,27]. Therefore
we examined the role of optineurin in the modulation of TNFa-
induced NF-kB activation. The effect of ectopic expression of wild
type optineurin and its E50K mutant on TNFa-induced NF-kB
activation was determined. HeLa cells were transfected with NF-
Figure 3. Electrophoretic mobility shift assay. (A), Nucleotide
sequence of synthetic oligonucleotide corresponding to putative NF-kB
site in optineurin promoter is shown which is used for assay (Optn. NF-
kB). A mutant of this oligonucleotide (mutant) and a consensus NF-kB
oligonucleotide used for competition are also shown. (B) EMSA was
carried out using radiolabelled oligonucleotide with nuclear extracts
from A549 cell treated with TNFa for 15 minutes. A 50-fold excess of
unlabeled self (lane 4), mutant (lane 5) or consensus NF-kB (lane 3)
oligonucleotide was used for competition. The nuclear extract was
preincubated with p65 NF-kB antibody for 30 min at 37uC before
adding the labelled probe (lane 2). Arrow indicates gel shift. Arrowhead
indicates super shift. (C) EMSA was carried out as in panel B except that
control extract was also used (lane 2).
doi:10.1371/journal.pone.0005114.g003
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kB luciferase reporter construct along with or without optineurin
expression plasmids. After 22 hours of transfection these cells were
treated with TNFa for 4 hours. Overexpression of optineurin or
E50K mutant did not affect the basal NF-kB reporter activity. In
response to TNFa the NF-kB reporter was activated to 3.7 fold.
This TNFa-induced NF-kB reporter activity was partially
inhibited by optineurin (Fig. 5A). These observations suggest that
optineurin negatively regulates TNFa-induced NF-kB activation.
The inhibition of NF-kB activation by E50K mutant was
significantly more (P,0.05) than that observed with wild type
optineurin. This was not due to higher level of expression of
mutant optineurin (Figure 5B). To further validate these
observations, effect of overexpression of optineurin and its E50K
mutant on TNFa-induced nuclear translocation of NF-kB p65 was
investigated. HeLa cells grown on coverslips were transfected with
a plasmid expressing HA-tagged optineurin, and after 24 hours
these cells were treated with TNFa for 30 min. The cells were then
stained for optineurin (HA antibody) and NF-kB p65. Microscopic
examination of cells revealed that nuclear translocation of NF-kB
p65 was inhibited in most of the cells expressing exogenous
optineurin and its E50K mutant (Fig. 5C).
TNFa stimulus results in rapid phosphorylation and proteasome
mediated degradation of IkB proteins, resulting in nuclear
translocation of NF-kB subunits where they regulate the
expression of target genes. HeLa cells were infected with
adenoviruses expressing wild type or E50K mutant optineurin
and were treated with TNFa for 6 min and 12 min. A significant
amount of IkB-a was degraded by 6 min of TNFa stimulation and
by 12 min it was almost completely degraded. In cells overex-
pressing E50K mutant, substantial levels of IkB-a persisted even
after 12 min of TNFa treatment suggesting that E50K mutant
inhibits TNFa-induced IkB-a degradation (Fig. 5D). IkB-a levels
were higher in TNFa-treated cells expressing E50K mutant
compared to those expressing wild type optineurin. These results
suggest that E50K mutant optineurin inhibits TNFa-induced NF-
kB activation by possibly affecting an upstream event.
Ubiquitin-binding region is essential for inhibition of NF-
kB activation by E50K mutant
A recent study has shown that optineurin binds lysine 63-linked
polyubiquitin chains, and competes with NEMO for the binding of
Figure 4. NF-kB mediates optineurin gene expression. (A) NF-kB p65 activates optineurin promoter through NF-kB site. Optineurin minimal
promoter constructs pGL-DP or pGL-mDP (100 ng) were transfected without or with NF-kB p65 expression plasmid (100 ng) in A549 cells. After
24 hours of transfection cell lysates were prepared for reporter assays. Luciferase activities relative to control pGL-DP (taken as 1.0) are shown (n = 3).
(B) IkBa inhibits TNFa-induced NF-kB activity. pGL-DP was transfected without or with IkBa super repressor expression plasmid (100 ng). TNFa was
added 6 hours after transfection. Luciferase activities relative to control are shown (n= 3). (C) Blocking of NF-kB activation inhibits TNFa-induced
optineurin gene expression. A549 cells were preincubated with 25 mM MG132 or solvent DMSO (0.1%) for 30 minutes prior to treatment with TNFa.
After 6 hours of treatment with TNFa, RNA was isolated and the level of optineurin mRNA was determined by real time RT-PCR analysis. GAPDH was
used as a control. (D) A549 cells were treated with MG132 as in panel C and after 6 hours of treatment with TNFa cell lysates were subjected to
Western blotting. (E) A549 cells were treated with 100 mg/ml of SN-50 peptide for 30 minutes prior to treatment with TNFa for 6 hours. The picture
shows RT-PCR analysis for optineurin gene expression.
doi:10.1371/journal.pone.0005114.g004
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ubiquitinated RIP. A mutation in the conserved ubiquitin binding
region (D474N) abolishes ubiquitin binding ability of optineurin and
NF-kB activation [19]. Since E50K mutant optineurin inhibits
TNFa-induced NF-kB activation more strongly than wild type
optineurin, a mutant of optineurin containing both E50K and
D474N mutations was generated to gain further insights into the
regulation of TNFa-induced NF-kB signaling by mutant optineurin.
HeLa cells were transfected with D474N or E50K or E50K-D474N
mutants along with NF-kB luciferase reporter. As expected the
D474N mutant optineurin did not inhibit TNFa-induced NF-kB
activation. However, the E50K-D474N double mutant also did not
inhibit TNFa- induced NF-kB activation (Fig. 5A). The expression
of mutants was confirmed by Western blotting (Fig. 5B). To further
validate these observations, sub-cellular distribution of p65 subunit of
Figure 5. Optineurin and E50K mutant inhibit TNFa-induced NF-kB activity. (A) NF-kB-Luc reporter plasmid (25 ng) was transfected without
or with optineurin expression plasmid (100 ng) in HeLa cells. After 22 hours of transfection cells were treated with TNFa for 4 hours. Luciferase
activities relative to untreated control are shown (n= 3). (B) Western blot showing expression of optineurin and its mutants using HA tag antibody.
Cdk2 was used as control. (C) Optineurin and E50K mutant inhibit TNFa-induced nuclear translocation of NF-kB p65. HeLa cells grown on coverslips
were transfected with optineurin expression plasmid. After 24 hours of transfection cells were treated with TNFa for 30 min. The cells were then fixed
and stained for optineurin (HA tag, FITC green) and p65 (Cy3, red) and visualized using a fluorescence microscope. (D) HeLa cells were infected with
adenoviruses for expressing optineurin (Optn-AdV), its E50K mutant (E50K-AdV) or control virus (AdC). After 36 hours of infection, the cells were
treated with TNFa for 6 min or 12 min or left untreated. Cell lysates were then prepared for western blotting with antibodies for IkBa, HA tag and
Cdk2.
doi:10.1371/journal.pone.0005114.g005
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NF-kB was studied. HeLa cells were transfected with either D474N
or E50K-D474N mutants and 24 hrs after transfection, cells were
treated with TNFa for 30 min. Immunostaining of p65 showed that
in response to TNFa, p65 translocates to nucleus in cells expressing
D474N mutant and in those expressing E50K-D474N mutant
optineurin (Fig. 5C). These observations suggest that the inhibition of
NF-kB activation by E50K mutant requires a functional ubiquitin
binding region.
Downregulation of optineurin activates NF-kB
Since overexpression of optineurin inhibited TNFa-induced NF-
kB activity, we determined the effect of downregulation of
endogenous optineurin on basal and TNFa-induced NF-kB activity.
For this purpose two shRNAs were expressed which target two
different regions of optineurin mRNA. Infection of HeLa cells with
adenoviruses expressing shRNAs (Ad-shOptn1 and Ad-shOptn2)
resulted in significant decrease in optineurin protein level after
72 hours of infection, as determined by western blotting (Fig. 6A);
however there was no significant change in the level of IkBa or NF-
kB p65. A virus expressing shRNA of unrelated sequence of same
length was used as a control. To determine the effect of
downregulation of optineurin on NF-kB activity, HeLa cells were
infected with Ad-shOptn1, Ad-shOptn2 or control viruses. After
48 h of infection these cells were transfected with NF-kB reporter
plasmid along with b-galactosidase expression plasmid. After
another 22 hours, these cells were treated with TNFa for 4 hours.
Downregulation of optineurin by both shRNAs resulted in
significant increase (P,0.05) in basal as well as TNFa-induced
NF-kB activity (Fig. 6A, B). To determine the effect of optineurin
knockdown upon IkBa levels, HeLa cells were infected with the
required adenoviruses and after 72 hours treated with TNFa for
6 min. Western blot analysis showed that downregulation of
optineurin by both shRNAs resulted in enhanced degradation of
IkB upon TNFa stimulation (Fig. 6C). These results suggest that
endogenous optineurin inhibits TNFa-induced NF-kB activation
and this inhibition occurs at a step upstream of IkB degradation.
Discussion
To begin to understand the molecular mechanisms which
regulate optineurin gene expression we have cloned and
characterized optineurin gene promoter. This promoter is active
Figure 6. Knockdown of optineurin by shRNA enhances TNFa-induced NF-kB activity. (A) HeLa cells were infected with Ad-shOptn1, Ad-
shOptn2 or control viruses and after 72 hours cell lysates were subjected to western blotting using antibodies for optineurin, IkBa and p65 NF-kB.
Control virus (AdC sh) expresses shRNA of unrelated sequence of same length. (B) HeLa cells were infected with Ad-shOptn1, Ad-shOptn2 or control
viruses. After 48 h of infection these cells were transfected with NF-kB reporter plasmid (25 ng) along with b-galactosidase expression plasmid. After
22 hours of transfection the cells were treated with TNFa (10 ng/ml) for 4 hours. Cell lysates were then made for reporter assays. The data represent
luciferase activities relative to untreated control taken as 1.0 (n = 3). (C) HeLa cells were infected with indicated adenoviruses and after 72 hours
treated with TNFa for 6 min or left untreated. Cell lysates were subjected to western blot analysis using antibodies for IkB, optineurin and tubulin
(loading control). AdC, control virus not expressing any shRNA.
doi:10.1371/journal.pone.0005114.g006
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in HeLa as well A549 cells and is activated upon treatment of cells
by TNFa. This promoter does not have a TATA box or an
initiator element. It showed several putative Sp1 sites and one NF-
kB site. Mutation of NF-kB site resulted in loss of activation of
promoter by TNFa. In addition basal promoter activity was also
reduced. Overexpression of IkBa resulted in inhibition of basal as
well as TNFa-induced promoter activity. These results show that
NF-kB is a crucial regulator of optineurin promoter activity. The
location of NF-kB site immediately upstream of exon-1,
requirement of NF-kB site for basal promoter activity and lack
of an initiator element lead us to speculate that NF-kB might be
involved in initiation of transcription from this promoter.
Activation of optineurin promoter by TNFa suggests that
TNFa-induced induction of optineurin gene expression is likely
to be due to the activation of the promoter. A recent study has
identified several target genes of NF-kB including optineurin [28].
Deletion analysis resulted in identification of a minimal or core
promoter (2136 to +221) which is activated by TNFa and shows
higher basal activity than the longer promoter in both HeLa as
well as A549 cells. Higher basal activity of smaller promoter
suggests that negative regulatory elements are present between
2856 and 2136 region of the promoter. However the negative
regulatory elements present between 2856 and 2136 region do
not seem to play a role in TNFa-induced activation because the
core promoter shows as much activation by TNFa as the longer
promoter. Presence of a putative MyoD-binding site in optineurin
promoter might explain high level of optineurin mRNA reported
in skeletal muscle from human and monkey [1,2].
The NF-kB activity is increased in the trabecular meshwork
cells obtained from the eyes of glaucomatous patients of diverse
etiology [24]. Cells of the trabecular meshwork regulate aqueous
outflow which controls intraocular pressure. It was shown that
enhanced NF-kB activity, due to higher level of interleukin-1,
protects glaucomatous trabecular meshwork cells from apoptosis
induced by oxidative stress [24]. NF-kB p50-deficient mice
develop glaucoma-like optic neuropathy [29]. Thus NF-kB has
cytoprotective function in various tissues of the eye. Recently it has
been shown that over-expressed optineurin protects NIH 3T3 cells
from apoptosis induced by oxidative stress [4]. Whether NF-kB-
induced optineurin contributes to cytoprotection against oxidative
stress, is yet to be investigated.
Recently it has been shown that optineurin negatively regulates
basal as well as TNFa-induced NF-kB activity in some cell lines
like HeLa S3 and Hek293 [19]. Our results show that optineurin
inhibits TNFa-induced NF-kB activity in HeLa cells although
basal activity was not inhibited. However downregulation of
endogenous optineurin by shRNA resulted in upregulation of basal
as well as TNFa-induced NF-kB activity. It has been suggested that
TNFa-induced NF-kB activity is inhibited by optineurin due to its
competition with NEMO for binding to ubiquitinated RIP [19]. The
mechanism by which optineurin negatively regulates basal NF-kB
activity is yet to be determined. A glaucoma-associated mutant of
optineurin, E50K, showed significantly more inhibition of TNFa-
induced NF-kB activation in HeLa cells. However this may not have
any relevance to glaucoma.
NF-kB activation is associated with several diseases such as
chronic inflammation, cancer and glaucoma [24,30,31]. Induction
of optineurin gene expression by metastasis promoting protein
S100A4 [32] and the regulation of optineurin promoter by NF-kB
provide a basis for exploring the role of optineurin in cancer
development.
On the basis of our results we suggest that there is a negative
feedback loop in which TNFa-induced NF-kB activity induces
expression of optineurin, which itself functions as a negative
regulator of NF-kB. Some other negative regulators of NF-kB,
such as IkB and CylD, are also induced by NF-kB in response to
TNFa [22,27]. Since optineurin protein level increases signifi-
cantly after 18–24 hours of treatment with TNFa, it is likely that
optineurin plays a more significant role in modulating NF-kB
activity at a later stage.
In conclusion our results show that the induction of optineurin
gene expression and promoter activation by TNFa is mediated by
NF-kB through a binding site in the promoter. Our results also
suggest that the relationship between NF-kB and optineurin is
quite complex because NF-kB induces optineurin, which nega-
tively regulates NF-kB activity. Since NF-kB and optineurin have
been linked to glaucoma, their reciprocal regulation might have
relevance to etiopathogenesis of glaucoma.
Materials and Methods
Cell culture and transfections
A549 and HeLa cells were maintained at 37uC in a CO2
incubator in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum. The transfections were carried out
using Lipofectamine Plus reagent (Invitrogen, San Diego, CA,
USA) according to the manufacturer’s instructions. All the
plasmids for transfection were prepared by using Qiagen columns
(Hilden, Germany). Human TNFa (Sigma, St Louis, MO, USA or
Calbiochem) was added wherever indicated at a final concentra-
tion of 10–20 ng/mL).
RT-PCR (Reverse transcription-polymerase chain reaction)
Total RNA was isolated using the TRIzol reagent (Invitrogen).
Semiquantitative RT-PCR was carried out essentially as described
previously [33]. RNAwas reverse transcribed using reagents from the
first-strand cDNA synthesis kit (Invitrogen). Optineurin forward (59-
GCTGCAAATGGATGAAATGAAGCA-39) and reverse primer
(59-CCGCTCGAGAGATCAACACTTAAATGATGCAATCC-
39) were used for the amplification of human optineurin cDNA by
PCR. Real time PCR for optineurin gene expression was carried out
using primers, forward 59- GACACGTTACAGATTCACGTGA-
39 and reverse, 59- ACTGTGCCCGGCCTGTTTTC-39. GAPDH
was used as a control, forward 59- TCATCCATGACAACTTTGG-
TATC- 39 and reverse, 59- AGGGATGACCTTGCCCA-
CAGCCTTGGCA- 39.
Expression vectors and antibodies
Rabbit polyclonal optineurin antibody was from Abcam. NF-kB
p65 antibody for supershift, IRF-1, IkB and tubulin antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); HRP conjugated anti-mouse and anti-rabbit antibodies
were from Amersham Pharmacia Biotech (Piscataway, NJ, USA).
Human optineurin expression plasmid and its E50K mutant have
been described by us previously [25]. D474N mutation was
created by PCR as described [25]. Plasmids for expressing p65
NF-kB and I-kB super repressor in which two serines are mutated
[34] were provided by D. Karunagaran (Indian Institute of
Technology, Chennai, India).
Cloning of optineurin promoter, reporter plasmids and
reporter assays
The optineurin promoter was cloned from human genomic DNA
by utilizing the PCR. The primers used were: forward, Opt-F, 59-
CCGCTCGAGTCAGGCTTGGCCAGGCA39 Opt-R, 59-
CCCAAGCTTCTGCCGCCCGGCTTGGCTT39. The ampli-
fied promoter fragment of 1077 bp was cloned into the pMOSBlue
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vector (Amersham) and sequenced. The sequence of this promoter
matched completely with that present in the database (Homo
sapiens chromosome 10 genomic contig, reference assembly, Ref.
NT_077569.2 HS10_77618 from nucleotide 7504122 to 7505198).
Deletion construct (357 bp; named DP) was made from the full
length promoter (FP) using forward primer 59-CCGCTCGA-
GACGGACAGCGAGGGTGGGTA-39 and same reverse primer
as used for amplifying full length promoter. The optineurin
promoter fragment was then excised by digestion with HindIII
and XhoI, and subcloned into the pGL3-BASIC vector (Promega,
Madison, WI, USA). NF-kB site in both the FP and DP were
mutated by site directed mutagenesis with the primers, 59-GGG
CCC CTC AAA TTC CCC GGC G-39 and 59-CGC CGG GGA
ATT TGA GGG GCC C-39. The nucleotide sequence of all
constructs was confirmed by automated DNA sequencing. Putative
transcription factor binding sites were determined by using
MatInspector from Genomatics Software. For determining pro-
moter activity the cells grown in 24-well plates were transfected with
100 ng of the required pGL3 construct, 50 ng of pCMV.SPORT-
b-gal (Invitrogen) and with the required amount of the other
plasmids. The total amount of plasmid in each transfection was kept
constant (400 ng for each well of a 24-well plate) by adding control
plasmid. Lysates were generally made 24 hour post-transfection.
Preparation of lysates and luciferase assays were carried out as per
the instruction of manufacturer (Promega). Relative luciferase
activities were calculated after normalizing with b-galactosidase
enzyme activities.
Western blot analysis
Cells were washed twice with PBS and lysed in 16SDS sample
buffer. Proteins were separated on 10% SDS-polyacrylamide gels
and blotted onto nitrocellulose membranes, and processed further
for western blotting as described [33].
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was carried out as previously described in detail [35].
Briefly, nuclear extracts were prepared from A549 cells after
treatment with TNF-a for 15 min and then stored at 270uC.
EMSA was performed by incubating 2 ml of nuclear extract for
15 min at 37uC with 1 ng of 32P-end-labeled 22-mer double-
stranded oligonucleotide containing the NF-kB-binding site (59-
GGG CCC GGG AAA TTC CCC GGC G-39). The DNA-
protein complex formed was separated from free oligonucleotide
on 5% native polyacrylamide gel, and the gel was then dried. The
specificity of binding was examined by competition with the
unlabeled self, mutant and consensus oligonucleotides.
Generation of adenoviral vectors expressing shRNA
Downregulation of endogenous optineurin was achieved by
shRNA (small hairpin RNA) mediated knockdown. For this
purpose adenoviral vectors expressing shRNAs were generated. As
a first step the shRNA expression vectors targeting two different
regions of optineurin were generated essentially as described
[33,36]. The desired oligonucleotides were annealed and cloned
into BbsI-XbaI sites of U6 promoter plasmid mU6 pro. The
optineurin sequence targeted by shOptn1 was from nucleotides
1076–1094 and for shOptn2 was from 2046–2064 (GenBank
accession NM_001008211). The sequences of the oligonucleotides
used for cloning were:
for shOptn1,
59-tttGCACGGCATCGTCTAAATAttcaagagaTATT-
TAGACAATGCCGTGttttt-39 and
59-ctagaaaaaGCACGGCATTGTCTAAATAtctcttgaa-
TATTTAGACGATGCCGTGC-39,
For shOptn2,
5 9 - t t tGGCTTACCTCGTTCAAAGAt t caaga -
gaTCTTTGAACAAGGTAAGCCCttttt-39 and
59-ctagaaaaaGGGCTTACCTTGTTCAAAGAtctctt-
gaaTCTTTGAACGAGGTAAGCC-39.
The adenoviral vectors expressing shRNAs were generated by
using pAdEASY system [37] kindly provided by B. Vogelstein
(Howard Hughes Medical Institute and Sidney Kimmel Compre-
hensive Cancer Center, The John Hopkins Medical Institutions,
Baltimore, MD, USA). The transcriptional units of shOPTN1 and
shOPTN2 shRNAs from the pMU6 vector were subcloned into
the adenoviral vector as described previously [37,38]. The shRNA
cassettes were released along with the mU6 promoter by HindIII-
XbaI digestion and cloned into pAdTrack plasmid upstream of
CMV-GFP cassette. Recombinant plasmids were generated by
homologous recombination in AdEasier cells. The recombinant
adenoviral plasmids were linearized with PacI and transfected in
HEK293T cells using Lipofectamine 2000 (Invitrogen). Recom-
binant viruses were collected after 15 days by lysing these
HEK293T cells. A control virus was also made which expressed
unrelated shRNA of the same length. All these adenoviruses
express GFP to monitor the infection of cells.
Adenoviral vectors for expressing optineurin and its E50K mutant
were prepared as described [38] using pAdEASY system [37].
NF-kB reporter assays
The reporter plasmid NF-kB-luc containing five tandem
consensus NF-kB binding sites upstream of a luciferase reporter
gene was used for measuring NF-kB activity. HeLa cells grown in
24 well dishes were transfected with 25 ng of the NF-kB-luc
plasmid, 50 ng of pCMV.SPORT-b-gal (Invitrogen) along with
the required amount of other plasmids. The total amount of
plasmid in each transfection was kept constant (400 ng for each
well of a 24-well plate) by adding control plasmid. Lysates were
made 26 h post-transfection.
Indirect immunoflourescence and microscopy
For immunoflourescence staining HeLa cells grown on
coverslips were transfected with required plasmids and 30 hrs
after trasnfections, cells were treated with TNF-a for 30 min. Cells
were then washed in PBS and fixed in 3.7% formaldehyde. Fixed
cells were permeabilized and stained for p65 and optineurin by
serially incubating with antibodies to p65 (Santa Cruz), anti rabbit-
cy3 followed by mouse monoclonal HA (Roche) and anti mouse
fluorescein isothiocyanate [39,40]. The coverslips were then
observed in a Olympus BX60 microscope and images captured
using CoolSnap CCD camera.
Statistical analysis
Graphs represent average 6SD values. Statistical differences
were calculated using Student’s T-test. When significant differ-
ences were observed, P values for pair wise comparisons were
calculated by using two-tailed T-test. P values less than 0.05 was
considered significant.
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